clinical trial · NCT06354998
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
ModernaTX, Inc.·phase3·completed·n = 217
SARS-CoV-2Investigational mRNA-1273.815Licensed Spikevax Vaccine
brief summary
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
started
Apr 8, 2024
primary completion
May 10, 2024
completion
May 10, 2024
last updated
May 25, 2025
official title
Randomized, Observer-Blind, Active-Controlled, Clinical Trial to Assess the Immunogenicity of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol